Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Freeze and burn: new device targets lung cancer during bronchoscopy

NCT ID NCT07398027

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a device called the HybridTherm® system, which uses freezing and radiofrequency heat to destroy small lung tumors during a routine bronchoscopy. The procedure is done before the patient's planned surgery to remove the tumor. The main goals are to see if the device works as intended and to check for any serious bleeding. Only 20 people with early-stage lung cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HybridTherm® System (device that combines freezing and radiofrequency heat to destroy tumors)
What this could lead to
If successful, this could provide a less invasive way to treat small lung tumors, potentially reducing the need for more extensive surgery.
What could go wrong
This is a very early, small study (20 people) focused on feasibility, not effectiveness. The procedure carries risks like bleeding, and it's unknown if it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who require diagnostic bronchoscopy for suspicious lung lesions with mediastinal lymph node status confirmed as NO by one of the following: Prior PET-CT showing no FDG-avid mediastinal lymph nodes, OR intraoperative EBUS-TBNA with ROSE confirming negative lymph nodes (performed when clinically indicated per section 6.1). * Solitary pulmonary lesions ≤ 2.5cm with histologically or cytologically confirmed primary lung cancer. * Suitable candidate for surgical resection of the tumor targeted for ablation * Interdisciplinary tumor board consent * Ability to read, understand, and sign patient Informed Consent Form (ICF) * Age ≥ 18-years-old * ≥ 20 mm of free space between the calculated intended ablation zone and the lung parenchyma or any critical structures (pleura, vessels and main bronchi). Exclusion Criteria: * Pregnant or nursing (breast feeding) females * Central tumors abutting vital structures (main bronchus, pulmonary artery, esophagus, trachea) * Thoracic electronic implants (e.g., pacemakers, ICDs) * Uncorrectable coagulopathy or platelet count ≤ 50,000/mm³ * Patients receiving anticoagulant therapy or with pulmonary hypertension that, in the opinion of the Investigator, poses an unacceptable safety risk for bronchoscopy and ablation. * Severe, uncontrolled comorbidities * Active systemic infection * Prior radiation therapy (SBRT) in the intended ablation zone * Recent Investigational therapy within the last 30 days that the investigator deems could interfere with proceeding in the clinical investigation * Tumors associated with atelectasis, obstructive pneumonitis, pleural effusion, or fibrosis * Investigators determine that study participation poses safety risk * Any comorbidities judged by the principal Investigator to be contraindicated for bronchoscopy * Subject was judged unsuitable for study participation by the Investigator for any other reason

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Zurich

    Zurich, Raemistrasse, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.